Acerta Pharma B.V. (A member of the AstraZeneca Group) Email Format
Pharmaceutical ManufacturingNorth Brabant, Netherlands51-200 Employees
Acerta Pharma B.V. is a European research and development center within the AstraZeneca group focused on discovering and developing new therapies for haematological malignancies. The organization began operations in 2013 with the aim of combining advanced science, covalent technology, and an experienced team to deliver targeted cancer therapies. It is based in Oss, North Brabant, Netherlands, and maintains a mid-sized workforce. In collaboration with AstraZeneca R&D colleagues in Gaithersburg, San Francisco, Boston, Gothenburg, and Cambridge, it pursues innovative drug discovery focused on haematological oncology. A notable development is a 2020 global Phase II collaboration with Ascentage Pharma to evaluate lisaftoclax in combination with acalabrutinib for hematologic cancers. This collaboration highlights Acerta Pharma’s role in advancing treatment options for patients with specific blood cancers within the AstraZeneca hematology research ecosystem.